Skip to content
RushPR News – Lifestyle
Author:
MeiraGTx
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
March 26, 2026
←
Previous Page
1
2